Curing arthritis in mice

August 6, 2014
Rheumatoid arthritis causes inflammation of multiple joints, such as the knee joint, as shown here. Credit: istock/Raycat

With a new therapeutic product, researchers have managed to cure arthritis in mice for the first time. The scientists are now planning to test the efficacy of the drug in humans.

Rheumatoid arthritis is a condition that causes painful inflammation of several in the body. The joint capsule becomes swollen, and the disease can also destroy and as it progresses. Rheumatoid arthritis affects 0.5% to 1% of the world's population. Up to this point, doctors have used various drugs to slow or stop the progression of the disease. But now, ETH Zurich researchers have developed a therapy that takes the treatment of in to a new level: after receiving the medication, researchers consider the animals to be fully cured.

The drug is a biotechnologically produced active substance consisting of two fused components. One component is the body's own immune messenger interleukin 4 (IL-4); previous studies have shown that this messenger protects mice with rheumatoid arthritis against cartilage and bone damage. ETH scientists have coupled an antibody to IL-4 that, based on the key-lock principle, binds to a form of a protein that is found only in inflamed tissue in certain diseases (and in tumour tissue).

Localised drug delivery

"As a result of combination with the antibody, IL-4 reaches the site of the disease when the fusion molecule is injected into the body," says pharmacist Teresa Hemmerle, who has just completed her dissertation in the group of Dario Neri, a professor at the Institute of Pharmaceutical Sciences. Together with Fabia Doll, also a PhD pharmacist at ETH, she is the lead author of the study. "It allows us to concentrate the active substance at the site of the disease. The concentration in the rest of the body is minimal, which reduces side-effects," she says.

The researchers tested the new fusion molecule, which they refer to as an 'armed antibody', in a CTI project together with the ETH spin-off Philochem. They used a mouse model in which the animals developed swollen, inflamed toes and paws within a few days. Among other things, the researchers studied the fusion molecule in combination with dexamethasone, a cortisone-like anti-inflammatory drug that is already used to treat rheumatoid arthritis in humans. The researchers started treating each mouse as soon as they began showing signs of the disease in the form of swollen extremities.

Clinical trials in the next year

When used separately, the new fusion molecule and dexamethasone managed only to slow the progression of the disease in the affected animals. In contrast, the typical signs of arthritis, such as swollen toes and paws, disappeared completely within a few days when both medications were administered at the same time. Concentrations of a whole range of immune messengers in blood and inflamed tissue, which are changed in rheumatoid arthritis, returned to their normal levels. "In our mouse model, this combined treatment creates a long-term cure," says Hemmerle, who, since completing her dissertation, has been working at Philochem, where she continues the project.

Based on the promising results from the animal model, Philochem is currently preparing to test the new in clinical trials on people suffering from rheumatoid . According to the , these tests will begin in the next year.

Explore further: Research on inflammasomes opens therapeutic ways for treatment of rheumatoid arthritis

More information: Hemmerle T, Doll F, Neri D: Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis. PNAS, online publication 4 August 2014, DOI: 10.1073/pnas.1402783111

Related Stories

Research on inflammasomes opens therapeutic ways for treatment of rheumatoid arthritis

July 2, 2014
Patients with more or less severe forms of rheumatoid arthritis (RA) may have the same painful symptoms, but does this mean that the cause of their illness is the same? And therefore that they should all receive the same ...

Genetics can explain why infections trigger onset of different types of rheumatoid arthritis

March 26, 2014
(Medical Xpress)—A new international study has revealed how genetics could explain why different environmental exposures can trigger the onset of different forms of rheumatoid arthritis.

Molecules involved in rheumatoid arthritis angiogenesis identified

May 16, 2014
Two protein molecules that fit together as lock and key seem to promote the abnormal formation of blood vessels in joints affected by rheumatoid arthritis, according to researchers at the University of Illinois at Chicago ...

Prolactin reduces arthritis inflammation

August 1, 2013
Inflammatory joint diseases such as rheumatoid arthritis are the result of cartilage damage and loss. Chondrocytes are the only cells that are found in cartilage and their death is linked to decreased cartilage health.

Vigilance for kidney problems key for rheumatoid arthritis patients

April 9, 2014
Rheumatoid arthritis patients are likelier than the average person to develop chronic kidney disease, and more severe inflammation in the first year of rheumatoid arthritis, corticosteroid use, high blood pressure and obesity ...

Researcher examines the relationship between gum disease and arthritis

October 16, 2012
Adelaide scientists have found that mice with gum disease develop worse arthritis.

Recommended for you

Fluid in the knee holds clues for why osteoarthritis is more common in females

June 26, 2017
Researchers have more evidence that males and females are different, this time in the fluid that helps protect the cartilage in their knee joints.

Biologics before triple therapy not cost effective for rheumatoid arthritis

May 29, 2017
Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). ...

Drug for refractory psoriatic arthritis shows promise in clinical trial

May 24, 2017
In a pivotal phase-3 clinical trial led by a Stanford University School of Medicine investigator, patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced ...

Cross-species links identified for osteoarthritis

May 17, 2017
New research from the University of Liverpool, published today in the journal npj Systems Biology and Applications, has identified 'cell messages' that could help identify the early stages of osteoarthritis (OA).

Osteoarthritis could be prevented with good diet and exercise

May 12, 2017
Osteoarthritis can potentially be prevented with a good diet and regular exercise, a new expert review published in the Nature Reviews Rheumatology reports.

Rodents with trouble walking reveal potential treatment approach for most common joint disease

May 11, 2017
Maintaining the supply of a molecule that helps to nourish cartilage prevented osteoarthritis in animal models of the disease, according to a report published in Nature Communications online May 11.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

tmcgallagher
not rated yet Aug 12, 2014
I am more than willing to be a lab rat! Been diagnosed with ra for 13 years my ra and anti ccp levels are off the charts. I'm on my fourth biologic among lots of other meds and there's been no change. I've only gotten worse!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.